Leukemia

The efficacy of Imbruvica (ibrutinib) and Zydelig (idelalisib) in chronic lymphocytic leukemia (CLL) suggests the drugs could potentially replace chemoimmunotherapy completely for some patients.

Stuart Goldberg, hematologist/oncologist at John Theurer Cancer Center, discusses some of the common questions he gets from his patients with chronic myeloid leukemia.

The Food and Drug Administration granted a Fast Track Designation to CPX-351 for the treatment of elderly patients with relapsed acute myeloid leukemia (AML).

The vastly improved outlook for patients with chronic lymphocytic leukemia (CLL) was named the American Society of Clinical Oncology's inaugural "Cancer Advance of the Year."

The FDA has updated the label for Gazyva (obinutuzumab) plus chlorambucil to include data from stage 2 of the phase 3 CLL11 study, which detailed an improvement in progression-free survival as a frontline treatment for patients with chronic lymphocytic leukemia.

In a first-in-human study, the drug AG-221 generated long-lasting remissions in patients with acute myeloid leukemia (AML).

Zydelig was approved for several recurrent B-cell cancers, and now new data shows the drug also creates a response in older patients newly diagnosed with CLL or SLL.

The CAR T-cell therapy CTL019 demonstrated an impressive complete response rate in pediatric patients with relapsed/refractory acute lymphoblastic leukemia.

The FDA approved the anti-CD19 immunotherapy Blincyto (blinatumomab) as a treatment for Philadelphia chromosome-negative acute lymphoblastic leukemia.

The CAR T-cell therapy JCAR015 received breakthrough therapy designation as a treatment for patients with relapsed or refractory B-cell ALL.

Approved and investigational agents have improved outcomes for patients with follicular lymphoma; however a growing understanding of the origins and progression of the disease might offer further insights for future clinical development.

Project: EveryChild is collecting biologic samples, such as blood, tissue and other specimens, from children undergoing treatment.

When deciding on a cancer treatment—and determining its effectiveness—look for a biomarker.

Goals and milestone recognitions may help children with cancer get through treatment a little easier.

Gazyva may become a standard treatment for older, sicker patient with CLL.

Long-term and late effects from toxic regimens from childhood cancer treatments include heart damage, lung problems and infertility.

Pediatric cancer treatment has come a long way, but health problems persist in survivorship.

A recent report notes that certain health issues observed in young adult survivors are typically seen in much older individuals.

Updates from the annual meeting of the American Society of Hematology.

Liposomal anthracycline may allow for higher dosing with less cardiotoxicity in childhood AML patients.

The latest in cancer prevention, diagnosis & treatment.

Oral anticancer therapy is available to treat different types of cancer and metastatic disease.

Ponatinib continues to make improvements in phase 2 CML study.

A study shows that a chemotherapy-free regimen may be better in acute promyelocytic leukemia.

When considering a stem cell transplantation, patients with cancer must be willing to take a chance.

Cancer research updates from the San Antonio Breast Cancer Symposium and American Society of Hematology.

Childhood and young adult cancer survivors need fertility preservation information, but are they getting it from their oncologists?

A kid can bring out the best in people.

Creating Hope for Childhood Cancer